Nordicus Partners Corporation Corporate Update
Nordicus Partners reported positive preclinical efficacy for its lead asset QR-01 in two animal models of periodontitis, including reduced bone loss confirmed by micro-CT. The company plans to initiate Phase IIa clinical trials for QR-01 in patients at the University of Copenhagen in the first half of 2027. Subsidiary Bio-Convert received a toxicity waiver from the Danish Medicines Agency for QR-02 (targeting oral leukoplakia) and expects GMP manufacturing completion by December 2026, with Phase IIa trials also slated for H1 2027.
Key figures
- Qr01 trial start
- H1 2027
- Qr02 trial start
- H1 2027
- Olk conversion rate
- 30%
- Qr02 gmp completion
- December 2026
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.